Elite Journal of Medical Sciences. Volume 2 issue 2(2024), Pp. 36-45
https://epjournals.com/journals/EJMS

Beyond Traditional Screening: Unleashing the Potential of Cancer Antigen 27.29 for Early Breast Cancer Identification

*Emmanuel Ifeanyi Obeagu[1] and Getrude Uzoma Obeagu[2]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda.

[2]School of Nursing Science, Kampala International University, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

This paper explores the untapped potential of Cancer Antigen 27.29 (CA 27.29) as a marker for early identification of breast cancer, transcending conventional screening methods. Despite advancements in breast cancer detection, limitations persist in achieving early and accurate diagnoses. This review critically examines the role of CA 27.29, primarily associated with monitoring disease progression and treatment efficacy in advanced breast cancer. Emerging research suggests its promising utility in early-stage detection due to its correlation with tumor burden and disease presence. Leveraging sophisticated methodologies beyond conventional screening, such as liquid biopsies and advanced imaging techniques, unveils CA 27.29's potential as a biomarker for early breast cancer identification. This exploration underscores the need for comprehensive studies and clinical trials to validate and integrate CA 27.29 into routine screening protocols, potentially revolutionizing early breast cancer diagnosis and patient outcomes.

Keywords*: Breast Cancer, Cancer Antigen 27.29, Early Detection, Biomarkers, Screening, Diagnostic Innovation, Tumor Markers, Cancer Diagnosis, Precision Medicine*

Introduction

Breast cancer remains a significant health concern worldwide, with early detection serving as a pivotal factor in improving patient outcomes.[1-3] While conventional screening methodologies like mammography have been instrumental in identifying breast malignancies, their limitations in detecting early-stage tumors have prompted a quest for more sensitive and specific biomarkers. Cancer Antigen 27.29 (CA 27.29) has emerged as a promising candidate, offering potential

Citation: Obeagu EI, Obeagu GU. Beyond Traditional Screening: Unleashing the Potential of Cancer Antigen 27.29 for Early Breast Cancer Identification. Elite Journal of Health Science, 2024; 2(2): 36-45

avenues for revolutionizing the landscape of early breast cancer identification.[4] This paper delves into the exploration of CA 27.29 beyond its established role in monitoring disease progression and treatment response in advanced breast cancer. Recent research endeavors have illuminated its association with tumor burden and disease presence, suggesting its viability as a marker for early-stage breast cancer detection. By transcending the boundaries of conventional screening, innovative methodologies such as liquid biopsies and advanced imaging techniques provide a platform for harnessing the untapped potential of CA 27.29 in early breast cancer identification.

In this context, the paper critically assesses the accumulating evidence and explores the prospects of integrating CA 27.29 into routine screening protocols. By shedding light on the necessity for comprehensive studies and robust clinical trials, this exploration aims to underscore the significance of validating CA 27.29 as a biomarker, potentially reshaping the landscape of early breast cancer diagnosis and paving the way for improved patient care and outcomes.[5] Breast cancer stands as one of the most prevalent and concerning malignancies affecting individuals globally, irrespective of gender.[6] According to worldwide statistics, it ranks among the leading causes of cancer-related deaths among women. However, it's important to note that men can also develop breast cancer, although it's less common. The incidence of breast cancer varies across geographical regions and demographic factors.[7] Factors such as genetic predisposition, lifestyle choices, hormonal influences, and environmental elements contribute to its occurrence. Globally, millions of new cases are diagnosed annually, emphasizing the significant burden it places on public health systems worldwide.

Despite considerable advancements in medical science and technology, breast cancer poses several challenges.[8] One primary hurdle is the variability in tumor characteristics and individual responses to treatment. This variability underscores the necessity for personalized approaches in diagnosis and therapy. Additionally, limitations persist in the accuracy of conventional screening methods, such as mammography, especially in detecting early-stage tumors or in individuals with dense breast tissue. Access to healthcare, disparities in screening programs, and socio-economic factors further compound the challenge, leading to delayed diagnoses and suboptimal outcomes for certain populations.

Early detection remains the cornerstone in the fight against breast cancer. Detecting the disease at an early stage significantly enhances treatment options and improves survival rates. Timely identification allows for less aggressive and more effective treatment interventions, potentially reducing the need for extensive therapies. It's crucial to emphasize the role of regular screenings, self-examinations, and awareness programs in facilitating early detection. Innovative technologies, emerging biomarkers, and enhanced imaging techniques continue to evolve, offering promising avenues for improving early diagnosis and prognosis.[9] Breast cancer continues to pose a formidable challenge globally. Addressing these challenges necessitates a multi-faceted approach involving increased awareness, improved access to screening and healthcare, personalized treatment strategies, and ongoing research endeavors to enhance early detection methods.

Citation: Obeagu EI, Obeagu GU. Beyond Traditional Screening: Unleashing the Potential of Cancer Antigen 27.29 for Early Breast Cancer Identification. Elite Journal of Health Science, 2024; 2(2): 36-45

Emphasizing the importance of early detection remains pivotal in reducing the burden of breast cancer and improving patient outcomes.[10-11]

Cancer Antigen 27.29: Characteristics, Expression, and Significance in Breast Cancer

Cancer Antigen 27.29 (CA 27.29) is a glycoprotein biomarker that has garnered considerable attention in the realm of breast cancer diagnosis, prognosis, and monitoring of treatment response.[12] This antigen belongs to the family of mucins, which are high-molecular-weight glycoproteins known for their involvement in cell signaling, adhesion, and immune response modulation. The primary origin of CA 27.29 is attributed to the MUC1 gene, which encodes a transmembrane glycoprotein expressed on the surface of epithelial cells. In normal physiological conditions, MUC1 aids in maintaining cell integrity and plays a role in cell signaling. However, alterations in its expression and structure occur in various cancers, including breast cancer, leading to the release of fragments of this glycoprotein into the bloodstream.[13] In breast cancer, elevated levels of CA 27.29 have been observed, particularly in advanced stages of the disease. The overexpression of MUC1 and subsequent shedding of CA 27.29 into circulation correlate with increased tumor burden and disease progression. Consequently, CA 27.29 has been extensively studied as a serum biomarker for monitoring therapeutic efficacy, disease recurrence, and progression in patients diagnosed with breast cancer.[14]

The significance of CA 27.29 lies in its potential utility as a non-invasive tool for disease monitoring and response assessment during treatment. Serial measurements of CA 27.29 levels in the blood have been employed to track treatment responses and detect disease recurrence, aiding clinicians in making informed decisions regarding patient management. Moreover, recent research endeavors have explored the potential of CA 27.29 beyond its conventional role in advanced breast cancer. Emerging evidence suggests its promise as a marker for early-stage breast cancer detection, presenting opportunities to enhance existing diagnostic modalities and augment early intervention strategies. The multifaceted nature of CA 27.29 as a biomarker in breast cancer, encompassing diagnostic, prognostic, and monitoring aspects, underscores its importance in clinical practice. Understanding its characteristics, expression patterns, and significance in breast cancer paves the way for further exploration, potentially heralding novel avenues in early detection, personalized treatment, and improved patient outcomes.[14]

CA 27.29 as a Biomarker for Breast Cancer Detection

Elevated levels of CA 27.29 have been associated with advanced breast cancer stages. Monitoring changes in CA 27.29 levels over time may aid in assessing disease progression and treatment response.[15] Recent studies suggest that CA 27.29 may hold promise as a biomarker for early breast cancer identification. Elevated CA 27.29 levels in the blood have been correlated with the presence of breast tumors, offering potential for early detection in some cases. While not recommended as a standalone diagnostic tool due to limitations in sensitivity and specificity, CA 27.29 measurements can complement existing screening methods like mammography, potentially

improving overall detection rates. CA 27.29 levels can serve as a useful indicator during treatment. Changes in CA 27.29 concentrations may reflect response to therapy, allowing for adjustments or modifications in treatment strategies.[16]

Challenges and Considerations

CA 27.29 lacks perfect sensitivity and specificity, leading to false-positive or false-negative results. Its levels can be affected by various factors, including benign conditions, influencing its accuracy.[17] CA 27.29 levels might not consistently reflect disease status in all breast cancer cases. Some individuals with breast cancer may exhibit normal CA 27.29 levels, limiting its reliability as a standalone marker. Further robust clinical studies and validation are essential to establish CA 27.29's reliability as an effective biomarker for breast cancer detection, especially in early-stage disease.

Diagnostic Innovations Utilizing CA 27.29

Researchers are investigating the incorporation of CA 27.29 into early detection protocols. Combining CA 27.29 measurements with other imaging or biomarker techniques may enhance the accuracy of detecting breast cancer at earlier stages. Utilizing liquid biopsies to detect circulating tumor cells (CTCs) or cell-free DNA (cfDNA) that shed from tumors into the bloodstream. Integrating CA 27.29 measurements within liquid biopsies may provide a comprehensive overview of tumor presence, aiding in early diagnosis and monitoring treatment response.[18] Developing multi-marker panels combining CA 27.29 with other biomarkers or imaging techniques to improve diagnostic accuracy. Combining multiple biomarkers may enhance sensitivity and specificity, potentially improving early detection rates.[19] Exploring the integration of CA 27.29 measurements with advanced imaging technologies, such as positron emission tomography (PET) or magnetic resonance imaging (MRI), to create more sensitive and specific imaging approaches for early cancer detection and characterization.[16] Efforts to develop rapid and cost-effective point-of-care tests for CA 27.29 measurements. Such tests could facilitate easier and more widespread monitoring, especially in resource-limited settings or for frequent monitoring during treatment.[18] Implementing AI algorithms for data analysis, combining CA 27.29 measurements with other clinical parameters, imaging data, and biomarker profiles. AI-driven models may improve the accuracy of interpreting CA 27.29 levels for diagnosis and prognosis.[18]

Developing tools for real-time monitoring of treatment response. Serial measurements of CA 27.29 during treatment could aid in assessing the effectiveness of therapies and facilitating timely modifications if necessary.[19] While these innovations show promise, their widespread clinical application requires rigorous validation through large-scale clinical trials and studies. Integrating CA 27.29 into these innovative diagnostic approaches holds the potential to revolutionize early breast cancer detection, personalize treatment strategies, and improve patient outcomes. Continued research and development are essential to refine these approaches and validate their efficacy in clinical settings.

Citation: Obeagu EI, Obeagu GU. Beyond Traditional Screening: Unleashing the Potential of Cancer Antigen 27.29 for Early Breast Cancer Identification. Elite Journal of Health Science, 2024; 2(2): 36-45

Clinical Utility and Challenges

The clinical utility of CA 27.29, a biomarker in breast cancer, offers several advantages and challenges in its application. Here's a breakdown:

Clinical Utility:

CA 27.29 measurements serve as a valuable tool in monitoring disease progression, especially in advanced stages of breast cancer. Elevated levels often correlate with increased tumor burden and disease severity.20 It aids in assessing treatment response and disease recurrence. Serial measurements help clinicians gauge the effectiveness of therapies and make informed decisions regarding treatment adjustments. CA 27.29 levels have shown associations with prognosis. Higher levels may indicate a poorer prognosis, guiding clinicians in predicting disease outcomes and tailoring treatment plans accordingly.[20] While not a primary screening tool, CA 27.29 can complement existing diagnostic methods, potentially enhancing overall detection rates when use in combination with other imaging or biomarker techniques.

Challenges

CA 27.29 lacks perfect sensitivity and specificity, leading to false-positive or false-negative results. This limitation affects its accuracy as a standalone diagnostic marker.[21] Elevated CA 27.29 levels can be observed in various benign conditions, not exclusively indicating breast cancer.[22] Conditions like inflammation or other cancers might also contribute to increased CA 27.29 levels, leading to potential misinterpretation. CA 27.29 levels may vary between individuals and tumor types.[23] Some breast cancer cases may not exhibit elevated CA 27.29 levels, reducing its reliability as a universal marker. Lack of standardized cut-off values and variability in assay methodologies across laboratories can pose challenges in interpretation and comparability of results. The cost of testing and the availability of assays may limit widespread use, particularly in resource-constrained settings or for frequent monitoring. Robust clinical validation through large-scale trials and studies is necessary to establish its reliability and clinical utility as an effective biomarker in breast cancer. Addressing these challenges requires ongoing research, standardization of assay techniques, and a better understanding of CA 27.29's role in breast cancer biology. Integrating CA 27.29 within a multimodal approach that combines various biomarkers, imaging techniques, and clinical parameters may enhance its clinical utility and improve patient care in breast cancer management.

Beyond Screening: Potential Applications of CA 27.29

CA 27.29 is valuable in assessing treatment response. Serial measurements during therapy help gauge its effectiveness. Changes in CA 27.29 levels may indicate response or resistance to treatment, guiding adjustments in therapy.[24] Elevated CA 27.29 post-treatment may indicate a higher risk of disease recurrence. Monitoring these levels enables early detection of potential recurrence, allowing for timely intervention.[25] CA 27.29 levels correlate with prognosis. Higher

baseline levels or persistent elevation post-treatment may signify poorer outcomes, aiding in prognostication and treatment planning. Integrating CA 27.29 measurements with clinical parameters assists in making informed decisions regarding patient management, such as determining the need for additional therapies or closer monitoring. CA 27.29, alongside other biomarkers and imaging techniques, contributes to a more personalized approach in breast cancer management.[26] Tailoring treatments based on individual biomarker profiles may optimize patient outcomes.

CA 27.29 serves as a critical tool in clinical trials and research for assessing treatment efficacy, patient stratification, and identifying potential therapeutic targets. Regular monitoring of CA 27.29 levels in patients with a history of breast cancer aids in long-term health surveillance, providing insights into disease status and potential relapse.[27] Integrating CA 27.29 measurements with imaging modalities may enhance diagnostic accuracy, especially in cases where imaging results are inconclusive or when used alongside traditional imaging methods. Identifying patients with specific biomarker profiles, including CA 27.29, may pave the way for novel targeted therapies and precision medicine approaches. Monitoring CA 27.29 levels contributes to post-treatment follow-up care. Regular assessments help in monitoring disease progression or remission, guiding long-term care plans. Leveraging CA 27.29 in these diverse clinical applications highlights its multifaceted role beyond initial screening, providing valuable insights into disease management and contributing to improved patient care and outcomes in breast cancer. However, further research, standardization, and validation are essential to maximize its clinical utility in these various applications.[28-41]

Recommendations

Encourage the incorporation of CA 27.29 measurements into breast cancer management guidelines, specifying its role in monitoring treatment response and disease progression. Establish standardized protocols for CA 27.29 assays to ensure consistency across laboratories, enabling reliable interpretation and comparability of results. Conduct large-scale clinical trials to validate the clinical utility of CA 27.29 in diverse patient populations, including early-stage breast cancer, to ascertain its effectiveness as a diagnostic and prognostic marker. Emphasize the use of CA 27.29 as part of a multimodal approach, integrating it with other biomarkers, imaging techniques, and clinical parameters to improve accuracy in diagnosis, prognosis, and treatment monitoring.

Identify subgroups of patients who might benefit most from CA 27.29 monitoring, considering their specific tumor characteristics, treatment regimens, and risk profiles for disease recurrence. Educate patients about the role of CA 27.29 in breast cancer management. Discuss its limitations and benefits, ensuring patients understand its significance in monitoring and managing their condition. Encourage ongoing research into novel biomarkers, imaging technologies, and therapeutic approaches that complement CA 27.29 measurements, aiming for enhanced precision in breast cancer diagnostics and treatment. Conduct studies evaluating the cost-effectiveness of integrating CA 27.29 measurements into routine clinical practice, considering its impact on patient

outcomes and healthcare resource utilization. Provide training and education for healthcare professionals on interpreting CA 27.29 results and integrating them into clinical decision-making. Engage patient advocacy groups to disseminate information, provide support, and advocate for access to CA 27.29 testing and its potential role in personalized breast cancer care.

Conclusion

Cancer Antigen 27.29 (CA 27.29) exhibits significant promise as a biomarker in breast cancer diagnostics and management. Its multifaceted role extends beyond initial screening, encompassing monitoring disease progression, treatment response assessment, prognostication, and potential early detection capabilities. However, several challenges, including limitations in sensitivity, specificity, and standardization, need to be addressed to maximize its clinical utility. Integrating CA 27.29 within a multimodal approach, combining it with other biomarkers, imaging modalities, and clinical parameters, presents a comprehensive strategy to enhance its diagnostic accuracy and prognostic value. This integration facilitates a more personalized and precise approach to breast cancer management, aiding in tailored treatment strategies and improved patient outcomes.

Continued advancements in research, technology, and clinical validation will further elucidate the full scope of CA 27.29's applications, contributing to enhanced early detection, treatment monitoring, and personalized therapeutic interventions in breast cancer. Embracing these recommendations will propel CA 27.29 towards becoming an indispensable tool in the comprehensive management of breast cancer, ultimately improving patient care and outcomes.

References

1. Obeagu EI, Babar Q, Vincent CC, Udenze CL, Eze R, Okafor CJ, Ifionu BI, Amaeze AA, Amaeze FN. Therapeutic targets in breast cancer signaling: A review. Journal of Pharmaceutical Research International. 2021;33(56A):82-99.
2. Obeagu EI, Muhimbura E, Kagenderezo BP, Nakyeyune S, Obeagu GU. An Insight of Interleukin-6 and Fibrinogen: In Regulating the Immune System. J Biomed Sci. 2022;11(10):83.
3. Obeagu EI, Babar Q, Vincent CC, Anyanwu CO, Uduchi IO. Advances in Therapeutic Strategies of Immunotherapy in Cancer Treatment. World Journal of Pharmacy and Pharmaceutical Sciences. 2021;10(8):2144-64.
4. Milosevic B, Stojanovic B, Cvetkovic A, Jovanovic I, Spasic M, Stojanovic MD, Stankovic V, Sekulic M, Stojanovic BS, Zdravkovic N, Mitrovic M. The Enigma of Mammaglobin: Redefining the Biomarker Paradigm in Breast Carcinoma. International Journal of Molecular Sciences. 2023;24(17):13407.
5. Čelešnik H, Potočnik U. Blood-Based mRNA Tests as Emerging Diagnostic Tools for Personalised Medicine in Breast Cancer. Cancers. 2023;15(4):1087.

Citation: Obeagu EI, Obeagu GU. Beyond Traditional Screening: Unleashing the Potential of Cancer Antigen 27.29 for Early Breast Cancer Identification. Elite Journal of Health Science, 2024; 2(2): 36-45

6. Ginsburg O, Bray F, Coleman MP, Vanderpuye V, Eniu A, Kotha SR, Sarker M, Huong TT, Allemani C, Dvaladze A, Gralow J. The global burden of women's cancers: a grand challenge in global health. The Lancet. 2017;389(10071):847-60.
7. Lima SM, Kehm RD, Terry MB. Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns. EClinicalMedicine. 2021;38.
8. Becker S. A historic and scientific review of breast cancer: The next global healthcare challenge. International Journal of Gynecology & Obstetrics. 2015;131: S36-9.
9. Dey S. Preventing breast cancer in LMICs via screening and/or early detection: The real and the surreal. World journal of clinical oncology. 2014;5(3):509.
10. Noor F, Noor A, Ishaq AR, Farzeen I, Saleem MH, Ghaffar K, Aslam MF, Aslam S, Chen JT. Recent advances in diagnostic and therapeutic approaches for breast cancer: A comprehensive review. Current Pharmaceutical Design. 2021;27(20):2344-65.
11. Basu P, Zhang L, Hariprasad R, Carvalho AL, Barchuk A. A pragmatic approach to tackle the rising burden of breast cancer through prevention & early detection in countries 'in transition'. The Indian journal of medical research. 2020;152(4):343.
12. Subia B, Dahiya UR, Mishra S, Ayache J, Casquillas GV, Caballero D, Reis RL, Kundu SC. Breast tumor-on-chip models: From disease modeling to personalized drug screening. Journal of Controlled Release. 2021; 331:103-20.
13. Ratan C, Cicily K D D, Nair B, Nath L. MUC glycoproteins: Potential biomarkers and molecular targets for cancer therapy. Current cancer drug targets. 2021;21(2):132-52.
14. Rack B, Schindlbeck C, Jueckstock J, Genss EM, Hepp P, Lorenz R, Tesch H, Schneeweiss A, Beckmann MW, Lichtenegger W, Sommer H. Prevalence of CA 27.29 in primary breast cancer patients before the start of systemic treatment. Anticancer research. 2010;30(5):1837-41.
15. Rack B, Jückstock J, Trapp E, Weissenbacher T, Alunni-Fabbroni M, Schramm A, Widschwendter P, Lato K, Zwingers T, Lorenz R, Tesch H. CA27. 29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients. Tumor Biology. 2016; 37:13769-75.
16. Sauter ER. Reliable biomarkers to identify new and recurrent cancer. European journal of breast health. 2017;13(4):162.
17. Kabel AM. Tumor markers of breast cancer: New prospectives. Journal of Oncological Sciences. 2017;3(1):5-11.
18. Welter L, Xu L, McKinley D, Dago AE, Prabakar RK, Restrepo-Vassalli S, Xu K, Rodriguez-Lee M, Kolatkar A, Nevarez R, Ruiz C. Treatment response and tumor evolution: lessons from an extended series of multianalyte liquid biopsies in a metastatic breast cancer patient. Molecular Case Studies. 2020;6(6): a005819.
19. Sharifi Z, Talkhabi M, Taleahmad S. Identification of potential microRNA diagnostic panels and uncovering regulatory mechanisms in breast cancer pathogenesis. Scientific Reports. 2022;12(1):20135.
20. Jeong S, Park MJ, Song W, Kim HS. Current immunoassay methods and their applications to clinically used biomarkers of breast cancer. Clinical biochemistry. 2020; 78:43-57.

Citation: Obeagu EI, Obeagu GU. Beyond Traditional Screening: Unleashing the Potential of Cancer Antigen 27.29 for Early Breast Cancer Identification. Elite Journal of Health Science, 2024; 2(2): 36-45

21. Kabel AM. Tumor markers of breast cancer: New prospectives. Journal of Oncological Sciences. 2017;3(1):5-11.
22. Rack B, Schindlbeck C, Jueckstock J, Genss EM, Hepp P, Lorenz R, Tesch H, Schneeweiss A, Beckmann MW, Lichtenegger W, Sommer H. Prevalence of CA 27.29 in primary breast cancer patients before the start of systemic treatment. Anticancer research. 2010;30(5):1837-41.
23. Gaughran G, Aggarwal N, Shadbolt B, Stuart-Harris R. The utility of the tumor markers CA15. 3, CEA, CA-125 and CA19. 9 in metastatic breast cancer. Breast Cancer Management. 2020;9(4): BMT50.
24. Duffy MJ, Evoy D, McDermott EW. CA 15-3: uses and limitation as a biomarker for breast cancer. Clinica chimica acta. 2010;411(23-24):1869-74.
25. Graham LJ, Shupe MP, Schneble EJ, Flynt FL, Clemenshaw MN, Kirkpatrick AD, Gallagher C, Nissan A, Henry L, Stojadinovic A, Peoples GE. Current approaches and challenges in monitoring treatment responses in breast cancer. Journal of Cancer. 2014;5(1):58.
26. Tan W, Yang M, Yang H, Zhou F, Shen W. Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers. Cancer management and research. 2018:4333-47.
27. Seale KN, Tkaczuk KH. Circulating biomarkers in breast cancer. Clinical Breast Cancer. 2022;22(3): e319-31.
28. Obeagu EI, Obeagu GU. Breast cancer: A review of risk factors and diagnosis. Medicine. 2024 Jan 19;103(3):e36905.
29. Obeagu EI, Babar Q, Vincent CC, Udenze CL, Eze R, Okafor CJ, Ifionu BI, Amaeze AA, Amaeze FN. Therapeutic targets in breast cancer signaling: A review. Journal of Pharmaceutical Research International. 2021 Dec 13;33(56A):82-99.
30. Mohamed QH, Obeagu EI. Genetic Heterogeneity in Breast Cancer: Implications. Elite Journal of Health Science. 2024;2(1):20-24.
31. Mohamed AF, Obeagu EI. Genetic Influence on Breast Cancer Progression: A Molecular Perspective. Elite Journal of Medica Science. 2024;2(1):19-22.
32. Obeagu EI, Muhimbura E, Kagenderezo BP, Nakyeyune S, Obeagu GU. An Insight of Interleukin-6 and Fibrinogen: In Regulating the Immune System. J Biomed Sci. 2022;11(10):83.
33. Obeagu EI, Babar Q, Vincent CC, Anyanwu CO, Uduchi IO. Advances in Therapeutic Strategies of Immunotherapy in Cancer Treatment. World Journal of Pharmacy and Pharmaceutical Sciences. 2021;10(8):2144-64.
34. Aizaz M, Khan M, Khan FI, Munir A, Ahmad S, Obeagu EI. Burden of Breast Cancer: Developing Countries Perspective. International Journal of Innovative and Applied Research. 2023;11(1):31-7.
35. Obeagu EI, Obeagu GU. Breast cancer: A review of risk factors and diagnosis. Medicine. 2024 Jan 19;103(3): e36905.
36. Obeagu EI, Obeagu GU. Breastfeeding's protective role in alleviating breast cancer burden: A comprehensive review. Annals of Medicine and Surgery.:10-97.

Citation: Obeagu EI, Obeagu GU. Beyond Traditional Screening: Unleashing the Potential of Cancer Antigen 27.29 for Early Breast Cancer Identification. Elite Journal of Health Science, 2024; 2(2): 36-45

37. Obeagu EI, Ahmed YA, Obeagu GU, Bunu UO, Ugwu OP, Alum EU. Biomarkers of breast cancer: Overview. Int. J. Curr. Res. Biol. Med. 2023; 1:8-16.
38. Obeagu EI, Obeagu GU. Breaking Ground: PARP Inhibitors and Their Efficacy in Breast Cancer Stages. Elite Journal of Medicine. 2024;2(2):42-54.
39. Obeagu EI, Obeagu GU. BRCA Mastery: Redefining Breast Cancer Care through Cutting-edge Diagnosis and Management. Elite Journal of Medicine. 2024;2(2):55-66.
40. Mohamed QH, Obeagu EI. Genetic Heterogeneity in Breast Cancer: Implications. Elite Journal of Health Science. 2024;2(1):20-4.
41. Mohamed AF, Obeagu EI. Genetic Influence on Breast Cancer Progression: A Molecular Perspective. Elite Journal of Medica Science. 2024;2(1):19-22.

Citation: Obeagu EI, Obeagu GU. Beyond Traditional Screening: Unleashing the Potential of Cancer Antigen 27.29 for Early Breast Cancer Identification. Elite Journal of Health Science, 2024; 2(2): 36-45